Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely reflect reconstitution basics and timing per the label, but include several statements not supported by the label and a key stability detail that contradicts the label.
Category Scores
Accurate Statements
Mix the supplied solvent with the powder in the vial.
Directions for Reconstitution
Withdraw sterile air from vial with lyophilized powder and inject into vial with solvent. Remove 1 to 10 mL of solvent and add to vial with lyophilized powder; agitate gently until powder completely dissolved; do not shake.
Directions for Reconstitution
Gently swirl or roll the vial until the solution is clear; do not shake it.
Directions for Reconstitution
The resulting liquid should be used immediately or stored in the refrigerator and used within the time stated on the label.
Directions for Reconstitution
The package insert specifies the amount of solvent supplied for each strength.
HOW SUPPLIED
Discard the unused solution after that period.
Directions for Reconstitution
If particles remain after gentle swirling, continue rolling the vial between your palms for another minute.
Directions for Reconstitution
Throw the vial away if the solution contains particles.
Directions for Reconstitution
Unsupported Statements
Draw the solvent into a syringe and inject it slowly along the inner wall of the vial so the powder dissolves without foaming.
Not described in label; syringe method and specific injection technique are not provided.
For a 5,000 IU vial the common volume is 1 mL bacteriostatic water, yielding a 5,000 IU/mL solution.
Not stated in label; per-strength solvent type/volume is not specified.
For a 10,000 IU vial the volume is usually 2 mL.
Not stated in label; per-strength volumes are not provided; kit solvent is 10 mL total.
Confirm the exact volume on your specific kit before mixing.
Label does not provide explicit per-kit exact volumes for mixing.
Plain sterile water works for single-use doses that will be injected right away, but bacteriostatic water is preferred when any portion will be stored and reused, because the added preservative slows bacterial growth.
Label specifies solvent as water for injection with benzyl alcohol; no comparison of sterile vs bacteriostatic water is provided.
Persistent cloudiness or undissolved material means the solution should not be injected; contact the pharmacy or prescriber for a replacement.
Label states do not use if discoloration or particulates; it does not specify contacting for replacement.
Splitting allows smaller, more frequent injections that some protocols use to maintain steadier hormone levels.
No label guidance on splitting dosing.
After reconstitution, draw the desired portion into an insulin syringe and store the remainder in the original vial under refrigeration.
Label does not specify syringe type or remainder storage.
Throw the vial away if more than 30 days have passed since reconstitution.
Label allows up to 60 days; 30 days is not supported.
Pregnyl is manufactured by Merck Sharp & Dohme.
Manufacturer information is not provided on the label.
Pregnyl is marketed in many countries under that brand.
Brand marketing scope is not specified on the label.
Patent and exclusivity data are tracked on DrugPatentWatch.com.
Patent information is not part of the safety label.
Contradictions
Low
AI Statement
When mixed with bacteriostatic water and kept refrigerated at 2–8 °C, the solution remains stable for up to 30 days according to most prescribing information.
Label Reference
Directions for Reconstitution
Important Omissions
Exact stability duration per the label is 60 days refrigerated; the AI mentions 30 days, which is not supported by the label.
Importance:
Moderate
Details on exact per-strength solvent volumes beyond the provided kit description are not stated in the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims align with the label; the main safety risk stems from incorrect stability duration stated (30 days) and unsubstantiated procedural details.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Stability duration misstatement (30 days vs 60 days) and several non-labeled statements (per-strength solvent volumes, solvent type, and administration specifics).
Suggested Improvement
Limit statements to label content; ensure stability is cited as 60 days refrigerated; clarify solvent type and volumes per strength if provided by label; avoid non-labeled administration guidance.